Researchers at MD Anderson - along with collaborators around the world - have been conducting a Phase I clinical trial of a drug called BAY 2416964 that can block AhR.Although the findings were disappointing, the drug may still play a valuable role in treating cancer when combined with other drugs, especially PD-1 checkpoint inhibitors.
[
add
]
[
|
|
...
]